Gold Nanoparticles: A New Golden Era in Oncology?
Clara GerosaGuido CrisponiValeria Marina NurchiLuca SabaRosita CappaiFlaviana CauGavino FaaPeter Van EykenMario ScartozziGiuseppe FlorisDaniela FanniPublished in: Pharmaceuticals (Basel, Switzerland) (2020)
In recent years, the spectrum of possible applications of gold in diagnostics and therapeutic approaches in clinical practice has changed significantly, becoming surprisingly broad. Nowadays, gold-based therapeutic agents are used in the therapy of multiple human diseases, ranging from degenerative to infectious diseases and, in particular, to cancer. At the basis of these performances of gold, there is the development of new gold-based nanoparticles, characterized by a promising risk/benefit ratio that favors their introduction in clinical trials. Gold nanoparticles appear as attractive elements in nanomedicine, a branch of modern clinical medicine, which combines high selectivity in targeting tumor cells and low toxicity. Thanks to these peculiar characteristics, gold nanoparticles appear as the starting point for the development of new gold-based therapeutic strategies in oncology. Here, the new gold-based therapeutic agents developed in recent years are described, with particular emphasis on the possible applications in clinical practice as anticancer agents, with the aim that their application will give rise to a new golden age in oncology and a breakthrough in the fight against cancer.
Keyphrases
- gold nanoparticles
- clinical practice
- palliative care
- clinical trial
- silver nanoparticles
- infectious diseases
- papillary thyroid
- reduced graphene oxide
- stem cells
- squamous cell
- randomized controlled trial
- endothelial cells
- mesenchymal stem cells
- squamous cell carcinoma
- drug delivery
- lymph node metastasis
- induced pluripotent stem cells
- double blind